The Effect of Sugammadex Versus Neostigmine on Postoperative Pulmonary Complications

PHASE4CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

January 24, 2017

Primary Completion Date

April 30, 2018

Study Completion Date

April 30, 2018

Conditions
Postoperative ComplicationsNeuromuscular Blockade
Interventions
DRUG

Sugammadex

At the end of the surgical procedure at a depth of neuromuscular blockade after the reappearance of T2 on the train-of-four, Sugammadex will be dosed once at 2 mg/kg through an intravenous line with brisk flow

DRUG

Neostigmine

At the end of surgical procedure at a depth of neuromuscular blockade after the reappearance of T2 on the train-of-four, Neostigmine will be dosed once at 0.07 mg/kg to a maximum of 5 mg through an intravenous line with brisk flow. Glycopyrrolate will be administered with Neostigmine at a dose between 0.1 to 0.2 mg of Glycopyrrolate per 1.0 mg of Neostigmine administered.

Trial Locations (1)

97239

Oregon Health and Science University, Portland

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Oregon Health and Science University

OTHER

NCT02861131 - The Effect of Sugammadex Versus Neostigmine on Postoperative Pulmonary Complications | Biotech Hunter | Biotech Hunter